Core Viewpoint - Wuxi Cancer Intelligent Drive Technology Co., Ltd. (referred to as "Cancer Intelligent") has successfully completed nearly 100 million RMB in Series A financing, indicating strong market and investor confidence in its core technology and future potential [1][4]. Company Overview - Cancer Intelligent, established in 2019, focuses on intelligent drives and high-performance robotic joints, dedicated to the R&D and industrialization of key components such as harmonic reducers, micro low-pressure actuators, integrated encoders, force sensors, and integrated joints [1][3]. Investment Insights - The investment led by Ecovacs, with participation from other industry resources, reflects a strategic move to enhance capabilities in core robotic components, aiming for breakthroughs in transmission parts, reducers, and joints [4]. - Ecovacs' Vice President and CFO, Ma Jianjun, emphasized the importance of this investment in the context of advancing embodied intelligence and AI technologies [4]. Future Plans - The founder of Cancer Intelligent, Zhao Wei, expressed gratitude for the support from investors and outlined plans to increase R&D investment in integrated joints, high-performance servo systems, emerging sensor integration, and advanced motion planning algorithms [5]. - The company aims to expand production capacity by building a new automated production line for integrated joints and enhance its global market ecosystem [5].